FARMINGTON, Utah--(BUSINESS WIRE)--PACS announced operating results for the third quarter of 2025. PACS has completed its Restatement of financials and is current with SEC obligations. ...

PACS Group, Inc. Reports Third Quarter 2025 Results Completes Restatement of Previously Issued Financial Statements and Now Current with SEC Filing Obligations Audit Committee Completes Investigation Conference Call and Webcast Scheduled for Today, November 19, 2025, at 5:30 pm ET. FARMINGTON, Utah, November 19, 2025 – PACS Group, Inc. (NYSE: PACS) ("PACS" or the "Company"), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______. Commission file number 001-42011 _________________________ PACS Group, Inc. (Exact name of registrant as specified in its charter) ______ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______. Commission file number 001-42011 _________________________ PACS Group, Inc. (Exact name of registrant as specified in its charter) ___________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______. Commission file number 001-42011 _________________________ PACS Group, Inc. (Exact name of registrant as specified in its charter) __________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ___________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number 001-42011 PACS Group, Inc. (Exact name of registrant as specified in its ch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______. Commission file number 001-42011 _________________________ PACS Group, Inc. (Exact name of registrant as specified in its charter) ______ ...

Core Insights - QT Imaging Holdings, Inc. has announced a strategic collaboration with Intelerad Medical Systems to enhance breast health management through innovative imaging technology [1] Company Overview - QT Imaging is focused on transforming breast health management with radiation-free imaging technology [1] - Intelerad Medical Systems is recognized as a global leader in medical imaging solutions [1] Strategic Collaboration - The agreement involves the deployment of InteleShare Research picture archiving and communication systems (PACS) and Cloud PACS [1]

Core Thesis - PACS Group, Inc. is viewed positively due to its strong operational metrics, structural demand for post-acute care, and potential for significant stock price appreciation as regulatory uncertainties are resolved [1][5]. Company Overview - PACS Group, Inc. operates a network of 316 skilled nursing and assisted living facilities across the U.S., managing over 32,000 skilled nursing beds and 2,400 assisted living beds, serving nearly 30,000 patients daily [2]. - The company maintains an overall occupancy rate of 88.9%, with mature facilities achieving 95.1%, indicating strong demand and operational efficiency [2]. Quality and Performance - Approximately 65% of PACS facilities hold 4- or 5-star CMS ratings, reflecting high-quality performance [3]. - The company has experienced delays in SEC filings but has secured multiple NYSE extensions through November 19, 2025, indicating regulatory confidence in its progress [3]. Financial Health - PACS has resolved technical defaults with lenders through forbearance, demonstrating lender recognition of the company's long-term viability [4]. - The company has strengthened its leadership team and increased cash balances to $294 million, providing ample liquidity for operations and growth [4]. Market Position - PACS's stock is currently trading near $12, significantly below analyst targets of $30+, suggesting a mispricing due to past short-seller claims and filing delays rather than operational weaknesses [4]. - Compared to peers like $ENSG, which trade at higher valuations, PACS is considered undervalued, presenting a high-upside opportunity for equity investors [5]. Future Outlook - With expected clearance of filings, strong preliminary operating results, and strategic safeguards in place, PACS is positioned for sustained growth and potential re-rating to $20–30 per share or more [5].

Company Overview - PACS Group, Inc. is a leading post-acute care provider operating 316 facilities across 17 states, with over 32,000 skilled nursing beds and 2,400 assisted living beds, focusing on quality care [2] - The company has expanded rapidly since Q2 2024, adding 96 facilities to its portfolio [2] Financial Performance - As of June 30, PACS reported an occupancy rate of 88.9%, significantly higher than the industry average of 78% [3] - The company has cash reserves of $294.2 million, nearly double the levels at the end of 2024 [3] - Management projects record revenue and adjusted EBITDA for the first half of 2025 once financial filings are complete [3] Regulatory and Governance Issues - The New York Stock Exchange extended PACS's trading period to November 19, 2025, allowing more time for the company to complete financial restatements and SEC filings [3] - PACS is cooperating with an independent Audit Committee investigation into past financial matters [3] - Leadership changes occurred with the resignation of CFO Derick Apt after an internal policy investigation, and a former CFO has been appointed as interim [4]